Reply: Cost of Therapies in Acute Coronary Syndromes: A Relevant Factor Not Reflected in the Trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43916754" target="_blank" >RIV/00216208:11120/18:43916754 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/18:N0000127

Výsledek na webu

<a href="https://doi.org/10.1016/j.jacc.2018.04.002" target="_blank" >https://doi.org/10.1016/j.jacc.2018.04.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jacc.2018.04.002" target="_blank" >10.1016/j.jacc.2018.04.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Reply: Cost of Therapies in Acute Coronary Syndromes: A Relevant Factor Not Reflected in the Trials

Popis výsledku v původním jazyce

Patient participation in covering the cost associated with medical therapy after acute myocardial infarction (AMI) is a factor that limits the use of evidence-based recommendations in every day patient care. The significance of this factor is further exacerbated when long-term therapy is required. Nonadherence to recommended guidelines negatively influences patient prognosis. In long-term dual antiplatelet therapy (DAPT), within the scope of secondary prevention following MI, ignoring recommendations for the use of the new P2Y12 inhibitors, prasugrel and ticagrelor (and using clopidogrel), as well as shortening therapy duration to &lt;12 months, can be considered as not complying with the guidelines (especially when there are no contradictions or high bleeding risk). Recognizing the importance of out-of-pocket costs has led to initiatives that further proved that adherence to therapy increases after elimination of copayment. The ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study) trial documented greater compliance with the use of the new P2Y12 inhibitors and longer DAPT duration when out-of-pocket costs were compensated. The trial also pointed to the complexity of the adherence to therapy issue. Nearly 1 in 3 patients in the intervention arm did not use the copayment reduction option. The most important initial intervention will remain the decision to discuss the importance of medication adherence with our patients. Dr. Lozano and colleagues commented on the communication gap that exists between patients and physicians relative to the cost the patient will incur while using a prescribed medication.

Název v anglickém jazyce

Reply: Cost of Therapies in Acute Coronary Syndromes: A Relevant Factor Not Reflected in the Trials

Popis výsledku anglicky

Patient participation in covering the cost associated with medical therapy after acute myocardial infarction (AMI) is a factor that limits the use of evidence-based recommendations in every day patient care. The significance of this factor is further exacerbated when long-term therapy is required. Nonadherence to recommended guidelines negatively influences patient prognosis. In long-term dual antiplatelet therapy (DAPT), within the scope of secondary prevention following MI, ignoring recommendations for the use of the new P2Y12 inhibitors, prasugrel and ticagrelor (and using clopidogrel), as well as shortening therapy duration to &lt;12 months, can be considered as not complying with the guidelines (especially when there are no contradictions or high bleeding risk). Recognizing the importance of out-of-pocket costs has led to initiatives that further proved that adherence to therapy increases after elimination of copayment. The ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study) trial documented greater compliance with the use of the new P2Y12 inhibitors and longer DAPT duration when out-of-pocket costs were compensated. The trial also pointed to the complexity of the adherence to therapy issue. Nearly 1 in 3 patients in the intervention arm did not use the copayment reduction option. The most important initial intervention will remain the decision to discuss the importance of medication adherence with our patients. Dr. Lozano and colleagues commented on the communication gap that exists between patients and physicians relative to the cost the patient will incur while using a prescribed medication.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the American College of Cardiology

ISSN

0735-1097

e-ISSN

—

Svazek periodika

71

Číslo periodika v rámci svazku

23

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

2711-2712

Kód UT WoS článku

000434924500021

EID výsledku v databázi Scopus

2-s2.0-85047544321